The Future of Pediatric Epilepsy Surgery Through a Genetic Lens

Overview

Pediatric epilepsy affects approximately 4 in 1,000 children annually, with up to 30% developing medically refractory epilepsy. Advances in genetic understanding, particularly of the PI3K-AKT-mTOR pathway, are shaping new treatment approaches including targeted molecular therapies alongside traditional surgical options.

Background

Epilepsy is defined by two unprovoked, nonfebrile seizures and affects many children worldwide. Medically refractory epilepsy, characterized by failure of two appropriate medications, occurs in about 30% of pediatric cases. Standard care for these children involves referral to comprehensive epilepsy surgery centers where multidisciplinary evaluations determine surgical candidacy. Cortical dysplasia is the most common pathology encountered in pediatric epilepsy surgery, often requiring complex diagnostic and surgical approaches.

Data Highlights

Epilepsy affects 4 in 1,000 children annually; up to 30% develop medically refractory epilepsy with less than 5% chance of seizure freedom on medication alone. Surgical success rates for cortical dysplasia range from 50-80% depending on lesion characteristics and location.

Key Findings

• Medically refractory epilepsy is defined by failure of two appropriately dosed and tolerated antiseizure medications.
• Cortical dysplasia is the predominant pathology in pediatric epilepsy surgery, involving abnormal neuronal migration and maturation.
• Surgical success rates for epilepsy due to cortical dysplasia vary between 50-80%, influenced by lesion visibility on MRI and proximity to critical brain areas.
• The PI3K-AKT-mTOR molecular pathway plays a critical role in the development of cortical dysplasia and epilepsy phenotype.
• Emerging treatments include mTOR inhibitors, which have shown safety and potential efficacy in early-phase clinical trials for children with cortical dysplasia and refractory epilepsy.
• Future therapies may combine or even replace surgery with targeted molecular treatments based on genetic insights.

Clinical Implications

Clinicians should consider comprehensive genetic and molecular evaluations in pediatric patients with refractory epilepsy, especially those with cortical dysplasia. The integration of mTOR inhibitors offers a promising adjunct or alternative to surgery, potentially improving outcomes for children who do not achieve seizure freedom postoperatively. Multidisciplinary epilepsy centers remain essential for optimal evaluation and individualized treatment planning.

Conclusion

Genetic insights into pathways such as PI3K-AKT-mTOR are revolutionizing the management of pediatric epilepsy, offering hope for improved surgical outcomes and novel targeted therapies. Continued research and clinical trials will be pivotal in advancing care for children with refractory epilepsy.

Related Resources & Content

1. Hauptman J. -- The Future of Pediatric Epilepsy Surgery Through a Genetic Lens